Celldex Therapeutics vs Clene
Celldex Therapeutics is the larger business, with $1.5m of revenue in fiscal 2025 against $200,000 for Clene (7.7 times as much). Clene grew faster (-41.5% against -78.0%). Clene kept more of each dollar of sales as profit: a net margin of -13086.5% against -16748.0%.
| Latest fiscal year | Celldex TherapeuticsCLDX, 2025 | CleneCLNN, 2025 |
|---|---|---|
| Revenue | $1.5m | $200,000 |
| Revenue growth | -78.0% | -41.5% |
| Net income | −$259m | −$26.2m |
| Operating margin | -18599.8% | — |
| Net margin | -16748.0% | -13086.5% |
| Return on equity | -40.6% | — |
| Free cash flow | −$214m | −$18.6m |
| Cash | $28.9m | $5.2m |
| Total debt | $0 | $17.8m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 198 | 79 |
| Market value | $2.32bn | $47.9m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 2 sales | 1 buys, 62 sales |